ATE359807T1 - Modifizierte annexin-proteine und verhinderung und behandlung von thrombose - Google Patents

Modifizierte annexin-proteine und verhinderung und behandlung von thrombose

Info

Publication number
ATE359807T1
ATE359807T1 AT02721083T AT02721083T ATE359807T1 AT E359807 T1 ATE359807 T1 AT E359807T1 AT 02721083 T AT02721083 T AT 02721083T AT 02721083 T AT02721083 T AT 02721083T AT E359807 T1 ATE359807 T1 AT E359807T1
Authority
AT
Austria
Prior art keywords
annexin
modified
thrombosis
modified annexin
prevention
Prior art date
Application number
AT02721083T
Other languages
English (en)
Inventor
Anthony Allison
Original Assignee
Surromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surromed Inc filed Critical Surromed Inc
Application granted granted Critical
Publication of ATE359807T1 publication Critical patent/ATE359807T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02721083T 2001-02-21 2002-02-21 Modifizierte annexin-proteine und verhinderung und behandlung von thrombose ATE359807T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27040201P 2001-02-21 2001-02-21
US33258201P 2001-11-21 2001-11-21

Publications (1)

Publication Number Publication Date
ATE359807T1 true ATE359807T1 (de) 2007-05-15

Family

ID=26954268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02721083T ATE359807T1 (de) 2001-02-21 2002-02-21 Modifizierte annexin-proteine und verhinderung und behandlung von thrombose

Country Status (8)

Country Link
US (2) US6962903B2 (de)
EP (2) EP1839670A3 (de)
JP (3) JP2004528025A (de)
AT (1) ATE359807T1 (de)
AU (1) AU2002252035A1 (de)
DE (1) DE60219611T2 (de)
ES (1) ES2286247T3 (de)
WO (1) WO2002067857A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20050222030A1 (en) * 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
DE10162434A1 (de) * 2001-12-18 2003-09-25 November Ag Molekulare Medizin Expressionsvektor und Verfahren zur Herstellung eines Expressionsvektors
WO2005023096A2 (en) * 2003-09-09 2005-03-17 Point Biomedical Corporation Methods and compositions for ultrasound imaging of apoptosis
JP5134362B2 (ja) * 2004-03-11 2013-01-30 アラビタ・ファーマシューティカルズ・インコーポレーテッド 修飾アネキシンタンパク質および血栓症を防止するための方法
ES2356364T3 (es) * 2004-04-15 2011-04-07 Athera Biotechnologies Ab Anexina v para prevenir la ruptura de la placa.
US7393833B2 (en) * 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
BRPI0712987A2 (pt) 2006-06-21 2012-04-10 Musc Found For Res Dev tratamento de doenças direcionado ao fator h do complemento
KR100835879B1 (ko) 2006-10-10 2008-06-09 학교법인 한림대학교 아넥신 융합 단백질
CN101015686B (zh) * 2007-02-06 2010-05-19 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
WO2009105231A1 (en) 2008-02-20 2009-08-27 The General Hospital Corporation Compositions and methods for treating vascular disorders
PL3216457T3 (pl) 2008-02-22 2019-09-30 Annexin Pharmaceuticals Ab Związki i sposoby zapobiegania lub leczenia restenozy
EP2123258A1 (de) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomen zur Arzneimittelverabreichung
EP2350112A4 (de) * 2008-10-03 2013-01-16 Advanced Proteome Therapeutics Inc Ortsspezifische n-terminus-proteinmodifikationen und konjugatbildung
AU2009328507A1 (en) 2008-12-19 2011-07-14 Medirista Biotechnologies Ab Oxidized cardiolipin as a novel pro-inflammatory factor
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
WO2011057158A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
SG185483A1 (en) 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
JP5584026B2 (ja) * 2010-07-02 2014-09-03 株式会社ダイヘン 抵抗溶接制御方法
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
WO2012136819A1 (en) 2011-04-05 2012-10-11 Athera Biotechnologies Ab Therapeutic and prophylactic methods, uses and compositions comprising anexin a5
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
WO2016205062A1 (en) * 2015-06-15 2016-12-22 Shifa Biomedical Corporation Antithrombotic therapies
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
CN105906800A (zh) * 2016-05-06 2016-08-31 中国科学院长春应用化学研究所 一种基因传递系统及其制备方法
WO2018053597A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CN114672483B (zh) * 2022-05-31 2022-09-02 上海百力格生物技术有限公司 超声法核酸探针制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DE3315000A1 (de) * 1983-04-26 1984-10-31 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
US5066788A (en) * 1984-09-21 1991-11-19 Boehringer Ingelheim International Gmbh Blood coagulation inhibiting proteins, processes for preparing them and their uses
IE58862B1 (en) * 1984-09-21 1993-11-17 Boehringer Ingelheim Int Blood coagulation inhibiting proteins, processes for preparing them and their uses
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1265446A (en) * 1985-09-30 1990-02-06 Masahiro Maki Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
JPH08840B2 (ja) * 1986-11-14 1996-01-10 興和株式会社 抗ｐｃｉモノクローナル抗体、これを用いた抗ｐｃｉの精製法及び免疫学的測定法
DE3643182A1 (de) * 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
US4937324A (en) * 1987-02-06 1990-06-26 Zymogenetics, Inc. Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
JP2660514B2 (ja) * 1987-02-20 1997-10-08 興和株式会社 抗血液凝固作用を有するポリペプチド
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
DE3737239A1 (de) 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
ES2096556T3 (es) * 1988-02-26 1997-03-16 Biogen Inc Secuencias de adn, moleculas de adn recombinante y procedimientos para producir lipocortinas iii, iv, v y vi.
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE59002895D1 (de) * 1989-07-15 1993-11-04 Boehringer Ingelheim Int Verfahren zur reinigung von annexinen.
DE59001418D1 (de) * 1989-07-15 1993-06-17 Boehringer Ingelheim Int Antikoagulanz enthaltendes mittel.
DE3937607A1 (de) 1989-11-11 1991-05-16 Boehringer Ingelheim Int Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
DE3942081A1 (de) * 1989-12-20 1991-06-27 Behringwerke Ag Mittel zur verbesserung der wiederfindung von annexinen
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
EP0527940A1 (de) 1990-05-08 1993-02-24 Liposome Technology, Inc. Direkt sprühgetrocknetes arzneistoff/lipid pulver
EP0555328A1 (de) 1990-11-02 1993-08-18 Genentech, Inc. Blutplättchenaggregationshemmstoffe
US5360789A (en) * 1990-11-20 1994-11-01 Kowa Co., Ltd. Therapeutic agent for skin or corneal disease
JP2916947B2 (ja) * 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US5229367A (en) * 1991-01-21 1993-07-20 Sclavo S.P.A. Antiinflammatory peptide derived from human lipocortin V
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
JPH05508664A (ja) * 1991-05-09 1993-12-02 ボード・オブ・リージェンツ・オブ・ザ・ユニヴァーシティ・オブ・ワシントン リン脂質標的血栓溶解剤
JPH051096A (ja) 1991-06-26 1993-01-08 Kowa Co 抗血液凝固活性を持つオリゴペプチド
CA2134239C (en) * 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
SG46493A1 (en) 1992-07-08 1998-02-20 Innogenetics Nv Polypepides derived form endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions
JP3416912B2 (ja) 1992-10-08 2003-06-16 興和株式会社 抗血液凝固活性を持つオリゴペプチド
JPH0772149A (ja) 1993-06-30 1995-03-17 Nippon Shinyaku Co Ltd 肝癌又は肝硬変の診断薬及び診断法
JPH0772147A (ja) 1993-07-02 1995-03-17 Noboru Kaneko 抗アネキシンｖ抗体並びに該抗体の製法及び利用
US5849600A (en) * 1993-11-10 1998-12-15 The Mclean Hospital Corporation Diagnostic assays for Alzheimer's disease
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
EP0765166B1 (de) 1994-06-16 2003-05-21 Neorx Corporation Radioaktivmarkierte annexin-galaktose konjugate
ES2139957T3 (es) 1994-07-23 2000-02-16 Roche Diagnostics Gmbh Metodo para la determinacion del estado pretrombotico.
DE19541284C2 (de) 1995-11-06 1998-09-24 Kalden Joachim Robert Prof Dr Verfahren zur Immunmodulation
WO1997024440A1 (en) 1995-12-27 1997-07-10 Genentech, Inc. Ob protein derivatives having prolonged half-life
CA2259152C (en) 1996-07-05 2002-02-12 Philip E. Branton Adenovirus e4 proteins for inducing cell death
EP0948533A1 (de) 1996-12-30 1999-10-13 Innogenetics N.V. Annexin v bindende polypeptidfragmente des hbsag und ihre verwendung
CN1168495C (zh) * 1997-01-15 2004-09-29 凤凰药理学公司 被修饰的肿瘤坏死因子
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6242570B1 (en) * 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
WO1999002992A1 (en) 1997-07-11 1999-01-21 The Mount Sinai School Of Medicine Of The City University Of New York Assays for diagnosis of thrombophilic disease
US6511829B1 (en) * 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
CA2305715A1 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Host derived proteins binding hcv: medical, diagnostic and purification use
JP2002507405A (ja) 1998-03-27 2002-03-12 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 低酸素誘導ヒト遺伝子、タンパク質およびそれらの使用
US20040002056A1 (en) * 1998-05-12 2004-01-01 Lorens James B. Methods of screening for bioactive agents using cells transformed with self-inactivating viral vectors
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
ATE230614T1 (de) * 1998-07-13 2003-01-15 Univ Texas Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
IL125908A (en) 1998-08-24 2005-05-17 Nst Neurosurvival Technologies Peptides and pharmaceutical compositions comprising same
WO2000010673A1 (en) 1998-08-24 2000-03-02 Nst Neurosurvival Technologies Ltd. Apparatus and method for capturing particles with surface exposure of anionic phospholipids from biological fluids
EP1107983A2 (de) 1998-09-01 2001-06-20 Innogenetics N.V. Annexin bindende benzodiazepin und benzothiazepin derivate und hbsag peptide, deren zusammensetzungen und verwendung
US6387366B1 (en) 1998-12-31 2002-05-14 Alg Company Methods for reducing adverse side effects associated with cellular transplantation
CN1125084C (zh) * 1999-03-12 2003-10-22 中国科学院上海生物化学研究所 一种血栓靶向性溶栓融合蛋白
US6323313B1 (en) * 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
US6645465B2 (en) 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
CA2444483A1 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use

Also Published As

Publication number Publication date
JP2010189405A (ja) 2010-09-02
EP1379266B1 (de) 2007-04-18
JP2004528025A (ja) 2004-09-16
EP1839670A3 (de) 2009-11-11
EP1379266A2 (de) 2004-01-14
DE60219611T2 (de) 2007-12-27
WO2002067857A3 (en) 2002-11-07
ES2286247T3 (es) 2007-12-01
WO2002067857A2 (en) 2002-09-06
AU2002252035A1 (en) 2002-09-12
EP1379266A4 (de) 2004-05-06
US20030166532A1 (en) 2003-09-04
DE60219611D1 (de) 2007-05-31
US7407475B2 (en) 2008-08-05
US6962903B2 (en) 2005-11-08
JP2008263991A (ja) 2008-11-06
US20050197295A1 (en) 2005-09-08
EP1839670A2 (de) 2007-10-03

Similar Documents

Publication Publication Date Title
ATE359807T1 (de) Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
DE60132978D1 (de) Hybride expression von neisseria proteinen
ATE330630T1 (de) Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DK1329458T3 (da) Peptider som sænker blodglucoseniveauer
DE60019777D1 (de) Zusammensetzung enthaltend caseinprotein und molkenprotein
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
EP1100496A4 (de) Kleine moleküle die bcl-2 proteine hemmen
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DK1107996T3 (da) Humane anti-faktor IX/IXa-antistoffer
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
NO971059L (no) Modifiserte human-C3-proteiner
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
WO2002097044A3 (en) Alternative splice forms of proteins as basis for multiple therapeutic modalities
TR200002101T2 (tr) Dondurulmuş gıda ürünü.
ATE282327T1 (de) Modifizierung von schaumeigenschaften von proteinen
WO2000048625A3 (en) Inhibitors for use in hemostasis and immune function
WO2005086955A3 (en) Modified annexin proteins and methods for preventing thrombosis
ATE235915T1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
DE602004005821D1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
DE60020903D1 (de) Käse mit Abbauprodukten von Molkeprotein
ATE226591T1 (de) Oligopeptide hergeleitet von fragmenten des c- reaktiven proteins
ATE349521T1 (de) Mit cd40 und traf interagierende proteine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties